◀ Back to IKBKG

CYLD — IKBKG

Pathways - manually collected, often from reviews:

• NCI Pathway Database Canonical NF-kappaB pathway: CYLD (CYLD) → NEMO (IKBKG) (modification, activates) Kovalenko et al., Nature 2003
  Evidence: assay, physical interaction
• NCI Pathway Database Canonical NF-kappaB pathway: CYLD (CYLD) → NEMO (IKBKG) (modification, activates)
• Reactome Reaction: IKBKG → CYLD (reaction) Kovalenko et al., Nature 2003, Abbott et al., Curr Biol 2004*

Protein-Protein interactions - manually collected from original source literature:

Studies that report less than 10 interactions are marked with *

• IRef Bind Interaction: IKBKG — CYLD Kovalenko et al., Nature 2003
• IRef Bind_translation Interaction: IKBKG — CYLD (two hybrid) Kovalenko et al., Nature 2003
• IRef Bind_translation Interaction: IKBKG — CYLD (coimmunoprecipitation) Kovalenko et al., Nature 2003
• IRef Biogrid Interaction: CYLD — IKBKG (direct interaction, two hybrid) Wang et al., Molecular systems biology 2011
• IRef Biogrid Interaction: CYLD — IKBKG (physical association, affinity chromatography technology) Shibata et al., Nature communications 2012*
• IRef Biogrid Interaction: CYLD — IKBKG (direct interaction, two hybrid) Kovalenko et al., Nature 2003
• IRef Biogrid Interaction: CYLD — IKBKG (physical association, affinity chromatography technology) Kovalenko et al., Nature 2003
• IRef Biogrid Interaction: CYLD — IKBKG (physical association, affinity chromatography technology) Brummelkamp et al., Nature 2003
• IRef Biogrid Interaction: CYLD — IKBKG (direct interaction, enzymatic study) Kovalenko et al., Nature 2003
• IRef Biogrid Interaction: CYLD — IKBKG (direct interaction, pull down) Trompouki et al., Nature 2003
• IRef Biogrid Interaction: CYLD — IKBKG (physical association, affinity chromatography technology) Chu et al., Cancer Biol Ther 2006*
• IRef Hprd Interaction: CYLD — IKBKG (in vitro) Saito et al., Structure 2004*
• IRef Innatedb Interaction: IKBKG — CYLD (unknown, -) Brummelkamp et al., Nature 2003
• IRef Innatedb Interaction: IKBKG — CYLD (unknown, -) Trompouki et al., Nature 2003
• IRef Innatedb Interaction: IKBKG — CYLD (unknown, -) Reiley et al., Mol Cell Biol 2005*
• IRef Innatedb Interaction: IKBKG — CYLD (unknown, -) Saito et al., Structure 2004*
• IRef Intact Interaction: IKBKG — CYLD (physical association, two hybrid) Wang et al., Molecular systems biology 2011

Text-mined interactions from Literome

Courtois et al., Cell Mol Life Sci 2008 (Genetic Diseases, Inborn) : CYLD exhibits deubiquitinating activity and acts as a negative regulator of NF-kappaB and JNK signaling through its interaction with NEMO and TRAF2
Espinosa et al., Cancer Cell 2010 (Leukemia, T-Cell) : Hes1 exerts its effects by repressing the deubiquitinase CYLD , a negative IKK complex regulator